Paper Details

  1. Home
  2. Paper Details

Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.

Author: ChenChen, XuWei, YangJing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Thalidomide in combination with chemotherapy was found to be an alternative treatment option for elderly patients with acute myeloid leukemia (AML), with similar safety profile to chemotherapy alone.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Currently, the treatment decisions in elderly patients with acute myeloid leukemia (AML) are difficult and remain controversial. This study aims to evaluate the effect of thalidomide plus chemotherapy on elderly patients with AML. METHODS: 70 elderly AML patients (median age 71 years) w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000487804

データ提供：米国国立医学図書館（NLM）

Thalidomide: A New Ally in Treating Elderly AML Patients?

Acute myeloid leukemia (AML) is a serious blood cancer, particularly challenging in elderly patients. This study investigates the effectiveness of combining thalidomide, a drug with known anti-cancer properties, with conventional chemotherapy for treating elderly AML patients. The study enrolled 70 elderly AML patients, randomly assigning them to receive either chemotherapy alone or chemotherapy plus thalidomide. The researchers monitored the patients' response to treatment, survival rates, and potential side effects.

Thalidomide: A Promising Addition to Chemotherapy for Elderly AML Patients

The study reveals that the combination of thalidomide and chemotherapy resulted in comparable response rates to chemotherapy alone. However, the study observed a survival benefit in the group receiving thalidomide and chemotherapy. While the study emphasizes the need for further research, it suggests that thalidomide could be a valuable addition to the treatment regimen for elderly AML patients.

Navigating AML Treatment: Hope for Elderly Patients

This research offers a ray of hope for elderly AML patients. It suggests that thalidomide, when combined with chemotherapy, might improve overall survival rates without increasing toxicity. This study encourages further investigation into the role of thalidomide in AML treatment, potentially leading to more effective and personalized therapies for elderly patients.

Dr.Camel's Conclusion

Treating AML, especially in elderly patients, is like navigating a treacherous sandstorm with limited supplies. This research explores a promising strategy, like discovering a hidden oasis in the desert. Thalidomide, a drug with unique properties, might offer a way to strengthen our defenses against AML, potentially improving survival chances. While further research is needed, this study paves the way for a more hopeful journey through the treatment desert.

Date :
  1. Date Completed 2019-08-26
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29975953

DOI: Digital Object Identifier

10.1159/000487804

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.